China Animal Husbandry and Veterinary Medicine ›› 2021, Vol. 48 ›› Issue (3): 1034-1045.doi: 10.16431/j.cnki.1671-7236.2021.03.028
• Preventive Veterinary Medicine • Previous Articles Next Articles
WANG Ning1, ZHAO Pengpeng1, ZHANG Yanyan2, MA Xun1, WANG Zhengrong2, BO Xinwen2
Received:
2020-09-01
Online:
2021-03-20
Published:
2021-03-18
CLC Number:
WANG Ning, ZHAO Pengpeng, ZHANG Yanyan, MA Xun, WANG Zhengrong, BO Xinwen. Research Progress on DNA Vaccine Against Animal Parasite[J]. China Animal Husbandry and Veterinary Medicine, 2021, 48(3): 1034-1045.
[1] 高晓佩,管晓燕,白国辉,等.DNA疫苗的作用机制[J].中国组织工程研究,2018,22(8):1281-1286. GAO X P,GUAN X Y,BAI G H,et al.DNA vaccines:Mechanisms of action[J].Chinese Journal of Tissue Engineering Research,2018,22(8):1281-1286.(in Chinese) [2] ZHANG Z,LI Y,XIE Q,et al.The molecular characterization and immunity identification of rhoptry protein 22(ROP22) of Toxoplasma gondii as a DNA vaccine candidate against toxoplasmosis[J].Journal of Eukaryotic Microbiology,2019,60(1):147-157. [3] ABDULHAQQ S A,WEINER D B.DNA vaccines:Developing new strategies to enhance immune responses[J].Immunology Research,2008,42(1-3):219-232. [4] KINDT T J,GOLDSBY R A,OSBORNE B A.Kuby Immunology[M].6th Edition.New York:W.H.Freeman and Co.,2007. [5] LI L,PETROVSKY N.Molecular mechanisms for enhanced DNA vaccine immunogenicity[J].Expert Review Vaccines,2016,15(3):313-329. [6] WILLIAMS J A.Improving DNA vaccine performance through vector design[J].Current Gene Therapy,2014,14(3):170-189. [7] WEDRYCHOWICZ H.Antiparasitic DNA vaccines in 21st century[J].Acta Parasitologica,2015,60(2):179-189. [8] MCCAFFREY J,DONNELLY R F,MCCARTHY H O.Microneedles:An innovative platform for gene delivery[J].Drug Delivery and Translational Research,2015,5(4):424-437. [9] LAMBRICHT L,LOPES A,KOS S,et al.Clinical potential of electroporation for gene therapy and DNA vaccine delivery[J].Expert Opinion on Drug Delivery,2016,13(2):295-310. [10] LIU J,KJEKEN R,MATHENESE I,et al.Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immuno-deficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation[J].Journal of Virological Methods,2008,82(11):5643-5649. [11] HIRAO L A,WU L,KHAN A S,et al.Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques[J].Vaccine,2008,26(3):440-448. [12] MCBURNEY S P,SUNSHINE J E,GABRIEL S,et al.Evaluation of protection induced by a dengue virus serotype 2 envelope domain Ⅲ protein scaffold/DNA vaccine in non-human primates[J].Vaccine,2016,34(30):3500-3507. [13] YAGERR E J,STAGNAR C,FULLER G R.Optimizing particle-mediated epidermal delivery of an influenza DNA vaccine in ferrets[J].Methods and Protocols,2013,940:223-237. [14] FULLER D H,LOUDON P,SCHMAIJOHN C.Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases[J].Methods,2006,40(1):86-97. [15] CHOI A A,KNOWLTONL D R,MCNEALP M M.Particle bombardment-mediated DNA vaccination with rotavirus VP6 induces high levels of serum rotavirus IgG but fails to protect mice against challenge[J].Virology,1997,232(1):129-138. [16] KARKADA M,WEIR G M,QUINTON T,et al.A liposome-based platform,VacciMax,and its modified water-free platform DepoVax enhance efficacy of in vivo nucleic acid delivery[J].Vaccine,2010,31,28(38):6176-6182. [17] ZOLLIGER W D,BABCOCK J G,MORAN E E,et al.PhaseⅠstudy of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide[J].Vaccine,2012,30(4):712-721. [18] MA J,WANG H,ZHENG X,et al.CpG/Poly(I:C) mixed adjuvant priming enhances the immunogenicity of a DNA vaccine against eastern equine encephalitis virus in mice[J].International Journal of Immuno-pharmacology,2014,19(1):74-80. [19] CHEN L,ZHU J,LI Y,et al.Enhanced nasal mucosal delivery and immunogenicity of anti-caries DNA vaccine through incorporation of anionic liposomes in chitosan/DNA complexes[J].PLoS One,2013,8(8):e71953. [20] SUSCHAK J J,WILLIAMS J A,SCHMALJOHN C S.Advancements in DNA vaccine vectors,non-mechanical delivery methods,and molecular adjuvants to increase immunogenicity[J].Human Vaccines & Immunotherapeutics,2017,13(12):2837-2848. [21] RAMAMOORTH M,NARVEKAR A.Non viral vectors in gene therapy——An overview[J].Journal of Clinical and Diagnostic Research,2015,9(1):GE01-06. [22] PEARSON F E,MCNEILLY C L,CRICHTON M L,et al.Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice[J].PLoS One,2013,8(7):e67888. [23] ALARCON J B,WAINE G W,MCMANUS D P.DNA vaccines:Technology and application as anti-parasite and anti-microbial agents[J].Advances in Parasitology,1999,42:343-410. [24] ROBINSON H L,PERTMER T M.DNA vaccines for viral infections:Basic studies and applications[J].Advances in Virus Research,2000,55:1-74. [25] JUSTEWICZ D M,MORIN M J,ROBINSON H L,et al.Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin[J].Journal of Virology,1995,69(12):7712-7717. [26] GUO X,ZHONG J Y,LI J W.Hepatitis C virus infection and vaccine development[J].Clinical and Experimental Hepatology,2018,8(2):195-204. [27] LU S.Immunogenicity of DNA vaccines in humans:It takes two to tango[J].Human Vaccine,2008,4(6):449-452. [28] LEE J,ARUN KUMAR S,JHAN Y Y,et al.Engineering DNA vaccines against infectious diseases[J].Acta Biomater,2018,80:31-47. [29] 张悦,周必英.寄生虫14-3-3基因工程疫苗研究进展[J].中国病原生物学杂志,2019,14(2):229-233. ZHANG Y,ZHOU B Y.Research progress of parasite 14-3-3 genetic engineering vaccine[J].Chinese Journal of Pathogen Biology,2019,14(2):229-233.(in Chinese) [30] WORLD HEALTH ORGANIZATION.Artemisinin and artemisinin-based combination therapy resistance[R].2016. [31] SEDEGAH M,HEDSTROM R,HOBART S L.Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein[J].Proceedings of the National Academy of Sciences of the United States of America,2014,91(21):9866-9870. [32] SHEIKH I H,KAUSHAL D C,CHANDRA D.Immunogenicity of a plasmid DNA vaccine encoding 42 kDa fragment of Plasmodium vivax merozoite surface protein-1[J].Acta Tropica,2016,162:66-74. [33] ZHENG L,PANG W,QI Z.Effects of transmission-blocking vaccines simultaneously targeting pre- and post-fertilization antigens in the rodent malaria parasite Plasmodium yoelii[J].Parasites & Vectors,2016,9(1):433. [34] DATTA D,BANSAL G P,GERLOFF D L,et al.Immunogenicity and malaria transmission reducing potency of Pfs48/45and Pfs25 encoded by DNA vaccines administered by intramuscular electropo-ration[J].Vaccine,2017,35(2):264-272. [35] DATTA D,BANSALL G P,GRASPERGE B,et al.Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques[J].Vaccine,2017,35(50):7049-7056. [36] REEDER S M,REUSCHE E L,BAH M A,et al.Synthetic DNA vaccines adjuvanted with pIL-33 drive liver-localized T cells and provide protection from Plasmodium challenge in a mouse model[J].Vaccines (Basel),2020,8(1):21. [37] 赵占中.新孢子虫NcSRS2 DNA疫苗的研究[D].北京:中国农业大学,2005. ZHAO Z Z.Study on the NcSRS2 DNA vaccine of Neospora[D].Beijing:China Agricultural University,2005.(in Chinese) [38] YANG Y,XUE X,YANG Y.Efficacy of a potential DNA vaccine encoding Cryptosporidium baileyi rhomboid protein against homologous challenge in chickens[J].Veterinary Parasitology,2016,225:5-11. [39] DUBEY J P,JONSE J L.Toxoplasma gondii infection in humans and animals in the United States[J].International Journal for Parasitology,2008,38(11):1257-1278. [40] RORAM E,ZAMIR C S,RILKIS I.Congenital toxoplasmosis-prenatal aspects of Toxoplasma gondii infection[J].Reproduction Toxicology,2006,21(4):458-472. [41] AHMADPOUR E,SARVI S,HASHEMI SOTEH M B,et al.Evaluation of the immune response in BALB/c mice induced by a novel DNA vaccine expressing GRA14 against Toxoplasma gondii[J].Parasite Immunology,2017,39(4):e12419. [42] PAGHEH A S,SARVI S,GHOLAMI S,et al.Protective efficacy induced by DNA prime and recombinant protein boost vaccination with Toxoplasma gondii GRA14 in mice[J].Microbial Pathogen,2019,134:103601. [43] CHING X T,FONG M Y,LAU Y L.Evaluation of the protective effect of deoxyribonucleic acid vaccines encoding granule antigen 2 and 5 against acute toxoplasmosis in BALB/c mice[J].American Journal of Tropical Medicine and Hygiene,2017,96(6):1441-1447. [44] CHU J Q,HUANG S,YE W,et al.Evaluation of protective immune response induced by a DNA vaccine encoding GRA8 against acute toxoplasmosis in a murine model[J].Korean Journal of Parasitology,2018,56(4):325-334. [45] HU L Y,ZHANG N Z,ZHANG F K,et al.Resistance to chronic Toxoplasma gondii infection induced by a DNA vaccine expressing GRA16[J].BioMed Research International,2017,2017:1295038. [46] ZHOU J,LI C,LUO Y,et al.Antigenic epitope analysis and efficacy evaluation of GRA41 DNA vaccine against T.gondii infection[J].Acta Parasito-logica,2019,64(3):471-478. [47] XU X P,LIU W G,XU Q M,et al.Evaluation of immune protection against Toxoplasma gondii infection in mice induced by a multi-antigenic DNA vaccine containing TgGRA24,TgGRA25 and TgMIC6[J].Parasite,2019,26:58. [48] MAVI S A,MODARRESSI M H,MOHEBALI M,et al.Assessment of the immunogenicity and protective efficiency of a novel dual-promoter DNA vaccine,harboring SAG1 and GRA7 genes,from RH strain of Toxoplasma gondii in BALB/c mice[J].Infection and Drug Resistance,2019,12:2519-2530. [49] WANG L,LU G,ZHOU A,et al.Evaluation of immune responses induced by rhoptry protein 5 and rhoptry protein 7 DNA vaccines against Toxoplasma gondii[J].Parasite Immunology,2016,38(4):209-217. [50] RASHID I,MOIRÉ N,HÉRAUT B,et al.Enhancement of the protective efficacy of a ROP18 vaccine against chronic toxoplasmosis by nasal route[J].Medical Microbiology and Immunology,2017,206(1):53-62. [51] ZHU Y C,HE Y,LIU J F,et al.Adjuvantic cytokine IL-33 improves the protective immunity of cocktailed DNA vaccine of ROP5 and ROP18 against Toxoplasma gondii infection in mice[J].Parasite,2020,27:26. [52] ZHOU J,WANG L,ZHOU A,et al.Bioinformatics analysis and expression of a novel protein ROP48 in Toxoplasma gondii[J].Acta Parasitologica,2016,61(2):319-328. [53] YANG W B,ZHOU D H,ZOU Y,et al.Vaccination with a DNA vaccine encoding Toxoplasma gondii ROP54 induces protective immunity against toxoplasmosis in mice[J].Acta Tropica,2017,176:427-432. [54] AlIZADEH P,AHMADPOUR E,DARYANI A,et al.IL-17 and IL-22 elicited by a DNA vaccine encoding ROP13 associated with protection against Toxoplasma gondii in BALB/c mice[J].Cell Physiology,2019,234(7):10782-10788. [55] LU G,ZHOU J,ZHAO Y H,et al.DNA vaccine ROP29 from Toxoplasma gondii containing R848 enhances protective immunity in mice[J].Parasite Immunology,2018,40(10):e12578. [56] 石娜.弓形虫基因疫苗pBudCE4.1-AMA1-ROP18免疫小鼠的保护作用研究[D].济南:山东大学,2012. SHI N.The protective effect of Toxoplasma gondii gene vaccine pBudCE4.1-AMA1-ROP18 in mice immunized[D].Jinan:Shandong University,2012.(in Chinese) [57] LU G,ZHOU J,ZHOU A,et al.SAG5B and SAG5C combined vaccine protects mice against Toxoplasma gondii infection[J].Parasitology International,2017,66(5):596-602. [58] PAGHEH A S,SARVI S,SHARIF M,et al.Toxoplasma gondii surface antigen 1(SAG1) as a potential candidate to develop vaccine against toxoplasmosis:A systematic review[J].Comparative Immunology,Microbiology and Infectious Diseases,2020,69:101414. [59] WORLD HEALTH ORGANIZATION.Leishmaniasis[Z].2019. [60] JAIN K,JAIN N K.Vaccines for visceral leishmaniasis:A review[J].Immunology Methods,2015,422:1-12. [61] XU D,LIEW E Y.Genetic vaccination against leishmaniasis[J].Vaccine,1995,12(6):1534-1536. [62] GURUNATHAN S,SACKS D L,BROWN D R,et al.Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major[J].Journal of Experimental Medicine,1997,186(7):1137-1147. [63] SALENHI-SANGANI G,MOHEBALI M,JAJARMI V,et al.Immunization against Leishmania major infection in BALB/c mice using a subunit-based DNA vaccine derived from TSA,LmSTI1,KMP11,and LACK predominant antigens[J].Iranian Journal of Basic Medical Sciences,2019,22(12):1493-1501. [64] MARTINEZ-RODRIGO A,MAS A,FERNÁNDEZ-COTRINA J,et al.Strength and medium-term impact of HisAK70 immunization in dogs:Vaccine safety and biomarkers of effectiveness for ex vivo Leishmania infantum infection[J].Comparative Immunology,Microbiology and Infectious Diseases,2019,65:137-143. [65] DALIMI A,NASIRI V.Design,construction and immunogenicity assessment of pEGFP-N1-KMP11-GP96(fusion) as a DNA vaccine candidate against Leishmania major infection in BALB/c mice[J].Iranian Journal of Parasitology,2020,15(1):11-21. [66] KUMAR S,ZUTSHI S,PATIDAR A,et al.LmjMAPK10 offers protection against Leishmania donovani infection[J].Parasite Immunology,2020,42(2):e12687. [67] FREIRE-DE-LIMA L,FONSECA L M,OELTMANN T,et al.The trans-sialidase,the major Trypanosoma cruzi virulence factor:Three decades of studies[J].Glycobiology,2015,25(11):1142-1149. [68] COSTA F,FRANCHIN G,PEREIRA-CHIOCCOLA V,et al.Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice[J].Vaccine,1998,16(8):768-774. [69] ARCE-FONSECA M,CARBAJAL-HERNANDZE A C,LOZANO-CAMACHHO M,et al.DNA vaccine treatment in dogs experimentally infected with Trypanosoma cruzi[J].Immunology Research,2020,2020:9794575. [70] DONG H,YANG S,ZHAO Q,et al.Molecular characterization and protective efficacy of silent information regulator 2A from Eimeria tenella[J].Parasites & Vectors,2016,9(1):602. [71] ZHAO P,LI Y,ZHOU Y,et al.In vivo immunopro-tective comparison between recombinant protein and DNA vaccine of Eimeria tenella surface antigen 4[J].Veterinary Parasitology,2020,278:109032 [72] ZHANG B,YUAN C,SONG X,et al.Optimization of immunization procedure for Eimeria tenella DNA vaccine pVAX1-pEtK2-IL-2 and its stability[J].Acta Parasitologica,2019,64(4):745-752. [73] 李莉.我国家畜血吸虫病的防控历程与流行现状[J].中国畜禽种业,2020,16(6):8-9. LI L.The course of prevention and control of schistosomiasis in our country and the present situation[J].China Livestock and Poultry Seed Industry,2020,16(6):8-9.(in Chinese) [74] ZHU Y,SI J,HARN D A,et al.The protective immunity of a DNA vaccine encoding Schistosoma japonicum Chinese strain triosephosphate isomerase in infected BALB/c mice[J].Southeast Asian Journal of Tropical Medicine and Public Health,2004,35:518-522. [75] ZHANG R,YOSHIDA A,KUMAGAI T,et al.Vaccination with calpain induces a Th1 based protective immune response against Schistosoma japonicum[J].Infection and Immunity,2001,69(1):386-391. [76] ZHU Y,REN J,HARN D A,et al.Protective immunity induced with 23 kDa membrane protein DNA vaccine of Schistosoma japonicum Chinese strain in infected C57BL/6 mice[J].Southeast Asian Journal of Tropical Medicine and Public Health,2003,34(4):697-701. [77] ZHOU S H,LIU S X,SONG G C,et al.Protective immunity induced by the full length cDNA encoding paramyosin of Chinese Schistosoma japonicum[J].Vaccine,2000,18(27):3196-3204. [78] 韩海勃,曹建平.日本血吸虫硫氧还蛋白编码基因的克隆表达及其免疫原性研究[J].国际医学寄生虫病杂志,2006,33(1):17-19. HAN H B,CAO J P.Cloning and expression of thioredoxin encoding gene of Schistosoma japonicum and its immunogenicity[J].International Journal of Medical Parasitology,2006,33(1):17-19.(in Chinese) [79] 任建功,朱荫吕,HARN D A,等.日本血吸虫23 kDa膜蛋白DNA疫苗和蛋白质疫苗联合应用免疫保护作用的研究[J].中国血吸虫病防治杂志,2002,14(2):98-101. REN J G,ZHU Y L,HARN D A,et al.Study on the immunoprotective effect of combined application of 23 kDa membrane protein DNA vaccine and protein vaccine of Schistosoma japonicum[J].Chinese Journal of Schistosomiasis Control,2002,14(2):98-101.(in Chinese) [80] 程红兵,周云飞,张树菊,等.pVAX1/IL-18对日本血吸虫DNA疫苗效果影响的初步研究[J].中国人兽共患病学报,2018,34(9):774-777. CHENG H B,ZHOU Y F,ZHANG S J,et al.Preliminary study on the effect of pVAX1/IL-18 on the DNA vaccine of Schistosoma japonicum[J].Chinese Journal of Zoonoses,2018,34(9):774-777.(in Chinese) [81] 宰金丽.日本血吸虫TOR分子DNA疫苗和RNA干扰研究[D].北京:中国农业科学院,2017. ZAI J L.Study on DNA vaccine and RNA interference of TOR molecule of Schistosoma japonicum[D].Beijing:Chinese Academy of Agricultural Sciences,2017.(in Chinese) [82] XU D,TANG B,WANG Y,et al.The immune protection induced by a serine protease from the Trichinella spiralis adult administered as DNA and protein vaccine[J].Acta Tropica,2020,211:105622. [83] 冯胜勇.miR-36f对猪蛔虫幼虫发育的调控及其靶基因核酸疫苗免疫效果评价[D].北京:中国农业科学院,2016. FENG S Y.Regulation of miR-36f on the development of Ascaris suum larvae and evaluation of the immune effect of target gene nucleic acid vaccine[D].Beijing:Chinese Academy of Agricultural Sciences,2016.(in Chinese) [84] 郭瀛军.猪带绦虫囊虫病DNA疫苗的中试及免疫效力研究[D].上海:第二军医大学,2004. GUO Y J.Pilot test and immune efficacy of DNA vaccine against Taenia solium cysticercosis[D].Shanghai:Second Military Medical University,2004.(in Chinese) [85] 李文桂,陈雅棠.多房棘球绦虫疫苗研究进展[J].地方病通报,2002,17(2):87-89. LI W G,CHEN Y T.Research progress of Echinococcus multilocularis vaccine[J].Bulletin of Disease Control & Prevention (China),2002,17(2):87-89.(in Chinese) [86] 王昌源.多房棘球绦虫亚单位疫苗及DNA疫苗初步研究[D].重庆:重庆医科大学,2003. WANG C Y.Preliminary study on Echinococcus multilocularis subunit vaccine and DNA vaccine[D].Chongqing:Chongqing Medical University,2003.(in Chinese) |
[1] | MA Zhanbang, XU Liwen, WANG Fangfang, ZHANG Lili, HOU Yutong, HAN Zongxi, MA Deying. Effects of Different Origins of Infectious Bronchitis Virus on Immune Function in SPF Chicken [J]. China Animal Husbandry and Veterinary Medicine, 2021, 48(12): 4628-4640. |
[2] | YANG Hai, WANG Fang-yu. Research Progress of DNA Vaccine [J]. , 2013, 40(1): 72-76. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 119
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 226
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||